GILDGilead SciencesSigning up patients
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ovarian Cancer · Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 334 (planned)
- Started
- Jun 12, 2024
- Main results expected
- Dec 2027
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs)
Measured over: First dose up to 21 days
Phase 1 and 2a: Percentage of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs)
Measured over: First dose date up to 30 days post last dose (Up to 3 years)
Phase 2a & 2b: Overall Response Rate (ORR) by Blinded Independent Central Review (BICR)
Measured over: Up to 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06303505 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC